Preferred Label : pyrazoles;
MeSH definition : Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with
IMIDAZOLES in which they are at the 1,3 positions.;
Wikipedia automatic translation : Pyrazole;
MeSH annotation : includes pyrazolines & pyrazolidines;
Wikipedia link : https://en.wikipedia.org/wiki/Pyrazole;
Codes EINECS : 206-017-1;
Is substance : O;
Origin ID : D011720;
UMLS CUI : C0034242;
ATC code(s)
Allowable qualifiers
Currated CISMeF NLP mapping
Record concept(s)
Related MeSH Supplementary Concept(s)
- 1-phenyl-3,5,8-trimethyl-1,4,5,6,7,8-hexahydropyrazolo(3,4-e)(1,4)diazepin-4,7-dione [MeSH Supplementary Concept]
- A 4334 [MeSH Supplementary Concept]
- A-83-01 [MeSH Supplementary Concept]
- AAP1742 [MeSH Supplementary Concept]
- AHC 52 [MeSH Supplementary Concept]
- AHC 93 [MeSH Supplementary Concept]
- AKI603 [MeSH Supplementary Concept]
- AM 1387 [MeSH Supplementary Concept]
- AM 251 [MeSH Supplementary Concept]
- AM 281 [MeSH Supplementary Concept]
- AM 6527 [MeSH Supplementary Concept]
- AM4113 [MeSH Supplementary Concept]
- AM6538 [MeSH Supplementary Concept]
- AM6545 [MeSH Supplementary Concept]
- APD668 [MeSH Supplementary Concept]
- APD791 [MeSH Supplementary Concept]
- APY0201 [MeSH Supplementary Concept]
- ASP5878 [MeSH Supplementary Concept]
- AT 7867 [MeSH Supplementary Concept]
- AT13148 [MeSH Supplementary Concept]
- AVN-492 [MeSH Supplementary Concept]
- AZD4547 [MeSH Supplementary Concept]
- AZD5153 [MeSH Supplementary Concept]
- AZD5718 [MeSH Supplementary Concept]
- AZD7451 [MeSH Supplementary Concept]
- AZD9362 [MeSH Supplementary Concept]
- AZD9819 [MeSH Supplementary Concept]
- BAY-876 [MeSH Supplementary Concept]
- BI-1347 [MeSH Supplementary Concept]
- BK-1517 [MeSH Supplementary Concept]
- BML-275 [MeSH Supplementary Concept]
- BPC 151 [MeSH Supplementary Concept]
- BS-181 [MeSH Supplementary Concept]
- BW 540C [MeSH Supplementary Concept]
- CAN 508 [MeSH Supplementary Concept]
- CD-101 [MeSH Supplementary Concept]
- CM-414 [MeSH Supplementary Concept]
- CMP 42 [MeSH Supplementary Concept]
- CNB 001 [MeSH Supplementary Concept]
- CPU0213 [MeSH Supplementary Concept]
- CSN5i-3 [MeSH Supplementary Concept]
- CW008 [MeSH Supplementary Concept]
- DGS-658 [MeSH Supplementary Concept]
- DMP 696 [MeSH Supplementary Concept]
- DP 802 [MeSH Supplementary Concept]
- DPC 602 [MeSH Supplementary Concept]
- DRD 156 [MeSH Supplementary Concept]
- DRD 157 [MeSH Supplementary Concept]
- DZ 3358 [MeSH Supplementary Concept]
- E7046 [MeSH Supplementary Concept]
- EBI-907 [MeSH Supplementary Concept]
- FK 352 [MeSH Supplementary Concept]
- FK 453 [MeSH Supplementary Concept]
- FK 838 [MeSH Supplementary Concept]
- G3129 [MeSH Supplementary Concept]
- G3130 [MeSH Supplementary Concept]
- GN39482 [MeSH Supplementary Concept]
- GNE-618 [MeSH Supplementary Concept]
- GNE-781 [MeSH Supplementary Concept]
- GNE-924 [MeSH Supplementary Concept]
- GSK 993 [MeSH Supplementary Concept]
- HA 22 [MeSH Supplementary Concept]
- HA 23 [MeSH Supplementary Concept]
- HA 29 [MeSH Supplementary Concept]
- HBSC11 [MeSH Supplementary Concept]
- IPI-549 [MeSH Supplementary Concept]
- JD-5006 [MeSH Supplementary Concept]
- JD5037 [MeSH Supplementary Concept]
- JDQ443 [MeSH Supplementary Concept]
- JTE 013 [MeSH Supplementary Concept]
- KDU731 [MeSH Supplementary Concept]
- KR33493 [MeSH Supplementary Concept]
- KW 2170 [MeSH Supplementary Concept]
- LC 6 [MeSH Supplementary Concept]
- LCQ789 [MeSH Supplementary Concept]
- LDC3140 [MeSH Supplementary Concept]
- LDC4297 [MeSH Supplementary Concept]
- LIMKi3 [MeSH Supplementary Concept]
- LIT-001 [MeSH Supplementary Concept]
- LQFM002 [MeSH Supplementary Concept]
- LQFM030 [MeSH Supplementary Concept]
- LQFM166 [MeSH Supplementary Concept]
- LUF6281 [MeSH Supplementary Concept]
- LUF6283 [MeSH Supplementary Concept]
- MBC94 [MeSH Supplementary Concept]
- MGV354 [MeSH Supplementary Concept]
- MK-8776 [MeSH Supplementary Concept]
- ML-792 [MeSH Supplementary Concept]
- MS-208 [MeSH Supplementary Concept]
- MT-3014 [MeSH Supplementary Concept]
- MU380 [MeSH Supplementary Concept]
- MW-19 [MeSH Supplementary Concept]
- NVS-SM2 [MeSH Supplementary Concept]
- O-6629 [MeSH Supplementary Concept]
- O-6658 [MeSH Supplementary Concept]
- ON09310 [MeSH Supplementary Concept]
- OT 7100 [MeSH Supplementary Concept]
- OT-82 [MeSH Supplementary Concept]
- PC 406 [MeSH Supplementary Concept]
- PDM-631 [MeSH Supplementary Concept]
- PZ 177 [MeSH Supplementary Concept]
- Phox-I1 [MeSH Supplementary Concept]
- QYM201 [MeSH Supplementary Concept]
- QYR301 [MeSH Supplementary Concept]
- RH 3421 [MeSH Supplementary Concept]
- RH1691 [MeSH Supplementary Concept]
- RH1838 [MeSH Supplementary Concept]
- RU-505 [MeSH Supplementary Concept]
- RepSox [MeSH Supplementary Concept]
- S 135 [MeSH Supplementary Concept]
- SB2001 [MeSH Supplementary Concept]
- SC 046 [MeSH Supplementary Concept]
- SC 558 [MeSH Supplementary Concept]
- SC 560 [MeSH Supplementary Concept]
- SCAOP [MeSH Supplementary Concept]
- SD 0006 [MeSH Supplementary Concept]
- SD5024 [MeSH Supplementary Concept]
- SLV 330 [MeSH Supplementary Concept]
- SR-318 [MeSH Supplementary Concept]
- TAK 593 [MeSH Supplementary Concept]
- TAK-071 [MeSH Supplementary Concept]
- TAK-243 [MeSH Supplementary Concept]
- TAS-116 [MeSH Supplementary Concept]
- TFM-735 [MeSH Supplementary Concept]
- TKM0150 [MeSH Supplementary Concept]
- TM38837 [MeSH Supplementary Concept]
- TPY-835 [MeSH Supplementary Concept]
- TRAM 34 [MeSH Supplementary Concept]
- UNC569 [MeSH Supplementary Concept]
- UR 7247 [MeSH Supplementary Concept]
- UR 7280 [MeSH Supplementary Concept]
- VRT 532 [MeSH Supplementary Concept]
- VX-659 [MeSH Supplementary Concept]
- WAY103 [MeSH Supplementary Concept]
- WYE-687 [MeSH Supplementary Concept]
- X 50 [MeSH Supplementary Concept]
- XC 386 [MeSH Supplementary Concept]
- Y 25510 [MeSH Supplementary Concept]
- Y08197 [MeSH Supplementary Concept]
- YL5084 [MeSH Supplementary Concept]
- YLL545 [MeSH Supplementary Concept]
- YMR-65 [MeSH Supplementary Concept]
- aminon [MeSH Supplementary Concept]
- amyorel [MeSH Supplementary Concept]
- spiro((3a,4,5,6,7,8,11,12,13,14,15,15a-dodecahydro-6,10,14-trimethyl-2-oxo-5,15-epoxy-3H-cyclotetradeca(b)furan)-3,3'-1'-pyrazoline)-6-yl
acetate [MeSH Supplementary Concept]
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
Validated automatic mappings to NTBT
Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with
IMIDAZOLES in which they are at the 1,3 positions.
https://ansm.sante.fr/tableau-acces-derogatoire/selpercatinib-20-40-et-80mg-gelule
2025
false
false
false
France
French
selpercatinib
administration, oral
carcinoma, non-small-cell lung
advanced RET fusion-positive non-small cell lung cancer
Product containing only selpercatinib in oral dose form (medicinal product form)
thyroid cancer, medullary
drug information
selpercatinib
pyrazoles
pyridines
---
https://ansm.sante.fr/tableau-atu-rtu/gavreto-100-mg-gelule
2024
false
false
false
France
French
pralsetinib
antineoplastic agents
guidelines for drug use
pralsetinib
pyrazoles
pyridines
pyrimidines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/orladeyo
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
berotralstat
berotralstat
drug approval
europe
angioedemas, hereditary
adult
adolescent
orphan drug production
administration, oral
berotralstat
drug monitoring
aged
drug interactions
pregnancy
breast feeding
plasma kallikrein
drug evaluation, preclinical
Substance with kallikrein inhibitor mechanism of action (substance)
pyrazoles
pyrazoles
---
https://www.has-sante.fr/jcms/p_3240237/fr/imbruvica-leucemie-lymphoide-chronique-llc
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
ibrutinib
ibrutinib
ibrutinib
guidelines for drug use
leukemia, lymphocytic, chronic, B-Cell
antineoplastic combined chemotherapy protocols
Rituximab
Ibrutinib/Rituximab Regimen
administration, oral
antineoplastic agents
antineoplastic agents
adult
survival analysis
evaluation of the transparency committee
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
---
2021
false
false
false
France
French
administration, oral
baricitinib
risk management
pregnancy
baricitinib
guidelines for drug use
breast feeding
patients guideline
dermatitis, atopic
arthritis, rheumatoid
baricitinib
Janus Kinase Inhibitors
Janus Kinase Inhibitors
drug monitoring
deep vein thrombosis
pulmonary embolism
cholesterol, HDL
cholesterol, LDL
Infections
vaccines, attenuated
venous thrombosis
azetidines
sulfonamides
purines
pyrazoles
azetidines
sulfonamides
purines
pyrazoles
---
https://www.has-sante.fr/jcms/p_3271751/fr/retsevmo-selpercatinib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
selpercatinib
administration, oral
RET Inhibitor
protein kinase inhibitors
antineoplastic agents
Proto-Oncogene Proteins c-ret
selpercatinib
Product containing precisely selpercatinib 80 milligram/1 each conventional release
oral capsule (clinical drug)
Product containing precisely selpercatinib 40 milligram/1 each conventional release
oral capsule (clinical drug)
adult
carcinoma, non-small-cell lung
Advanced Lung Non-Small Cell Carcinoma
adolescent
Advanced Thyroid Gland Medullary Carcinoma
thyroid neoplasms
RET Gene Mutation
carcinoma, non-small-cell lung
thyroid neoplasms
RET Fusion Positive
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
pyrazoles
pyridines
---
https://ansm.sante.fr/tableau-atu-rtu/berotralstat-150-mg-gelule
2021
false
false
false
France
French
Berotralstat
package leaflet
summary of product characteristics
guidelines for drug use
Berotralstat
pyrazoles
pyrazoles
administration, oral
angioedemas, hereditary
plasma kallikrein
Hereditary angioedema attack
berotralstat
berotralstat
berotralstat
---
https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
pyrazoles
pyrazoles
pyridines
pyridines
RET Inhibitor
RET Inhibitor
protein kinase inhibitors
protein kinase inhibitors
Proto-Oncogene Proteins c-ret
antineoplastic agents
antineoplastic agents
product surveillance, postmarketing
RET Gene Mutation
carcinoma, non-small-cell lung
mutation
carcinoma, non-small-cell lung
bronchial neoplasms
Advanced Lung Non-Small Cell Carcinoma
adult
adolescent
thyroid neoplasms
Advanced Thyroid Gland Medullary Carcinoma
Advanced Thyroid Gland Carcinoma
mutagenicity tests
administration, oral
aged
drug interactions
pregnancy
breast feeding
selpercatinib
drug evaluation, preclinical
selpercatinib
selpercatinib
Product containing precisely selpercatinib 40 milligram/1 each conventional release
oral capsule (clinical drug)
Product containing precisely selpercatinib 80 milligram/1 each conventional release
oral capsule (clinical drug)
advanced RET fusion-positive non-small cell lung cancer
advanced RET fusion-positive thyroid cancer
Tyrosine Kinase Inhibitors
---
https://www.has-sante.fr/jcms/p_3242174/fr/ayvakyt
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
administration, oral
avapritinib
guidelines for drug use
gastrointestinal stromal tumors
adult
Metastatic Gastrointestinal Stromal Tumor
neoplasm metastasis
Unresectable Malignant Gastrointestinal Stromal Tumor
mutation
PDGFRA NP_006197.1:p.D842V
PDGFRA Gene Mutation
receptor, platelet-derived growth factor alpha
pyrazoles
pyrroles
triazines
protein kinase inhibitors
antineoplastic agents
evaluation of the transparency committee
avapritinib
avapritinib
---
https://ansm.sante.fr/tableau-atu-rtu/voxelotor-500-mg-comprimes-pellicules
2021
false
false
false
France
French
voxelotor
anemia, sickle cell
Product containing only voxelotor in oral dose form (medicinal product form)
guidelines for drug use
voxelotor
benzaldehydes
pyrazines
pyrazoles
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/default-d6182e9e12-99.html
2021
false
false
false
Canada
French
drug evaluation
quebec
cystic fibrosis
adolescent
adult
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance
regulator gene
CFTR delta F508
drug combinations
trikafta
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
benzodioxoles
aminophenols
indoles
pyrazoles
pyridines
quinolines
benzodioxoles
aminophenols
drug combinations
indoles
pyrazoles
pyridines
quinolines
---
https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/infovigilance-produits-sante/juillet-2021.html#a6
2021
false
false
false
Canada
French
drug information
canada
Product containing precisely pralsetinib 100 milligram/1 each conventional release
oral capsule (clinical drug)
pralsetinib
lung neoplasms
pralsetinib
pyrazoles
pyridines
pyrimidines
---
https://www.has-sante.fr/jcms/p_3151443/fr/revolade
2020
false
false
false
France
eltrombopag
eltrombopag
thrombocytopenia
Thrombocytopenia Due to Immune Destruction
administration, oral
evaluation of the transparency committee
hydrazines
pyrazoles
benzoates
---
https://www.has-sante.fr/jcms/p_3222368/fr/adempas
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
riociguat
hypertension, pulmonary
evaluation of the transparency committee
riociguat
pyrazoles
pyrimidines
---
https://www.has-sante.fr/jcms/p_3220388/fr/kaftrio-/-kalydeco
2020
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
ivacaftor
Chloride Channel Agonists
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
cystic fibrosis
adolescent
adult
CFTR delta F508
cystic fibrosis transmembrane conductance regulator delta F508
administration, oral
elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
evaluation of the transparency committee
aminophenols
quinolones
indoles
benzodioxoles
cystic fibrosis transmembrane conductance regulator
pyrrolidines
pyridines
pyrazoles
drug combinations
quinolines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
pyrazoles
pyrazoles
pyrroles
pyrroles
triazines
triazines
antineoplastic agents
antineoplastic agents
gastrointestinal stromal tumors
orphan drug production
neoplasm metastasis
mutation
gastrointestinal stromal tumors
receptor, platelet-derived growth factor alpha
administration, oral
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor
avapritinib
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
PDGFRA NP_006197.1:p.D842V
avapritinib
avapritinib
---
https://www.has-sante.fr/jcms/p_3212149/fr/nubeqa
2020
false
false
false
France
administration, oral
treatment outcome
insurance, health, reimbursement
darolutamide
darolutamide
prostatic neoplasms, Castration-Resistant
antineoplastic combined chemotherapy protocols
evaluation of the transparency committee
pyrazoles
---
https://www.has-sante.fr/jcms/p_3210936/fr/adempas
2020
false
false
false
France
riociguat
insurance, health, reimbursement
adult
hypertension, pulmonary
Chronic thromboembolic pulmonary hypertension
thromboembolism
evaluation of the transparency committee
riociguat
pyrazoles
pyrimidines
---
https://www.ema.europa.eu/en/medicines/human/EPAR/apixaban-accord
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
apixaban
apixaban
Factor Xa Inhibitors
Factor Xa Inhibitors
drugs, generic
venous thromboembolism
postoperative complications
adult
arthroplasty, replacement, hip
arthroplasty, replacement, knee
pulmonary embolism
deep vein thrombosis
pulmonary embolism
deep vein thrombosis
atrial fibrillation
stroke
administration, oral
apixaban
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
venous thrombosis
venous thrombosis
pyrazoles
pyridones
pyrazoles
pyridones
---
https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form
(medicinal product form)
drug approval
europe
drug combinations
administration, oral
orphan drug production
pyrazoles
pyrazoles
pyridines
pyridines
pyrrolidines
pyrrolidines
ivacaftor
ivacaftor
tezacaftor
tezacaftor
adolescent
adult
cystic fibrosis
drug therapy, combination
cystic fibrosis transmembrane conductance regulator
ivacaftor, tezacaftor and elexacaftor
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
elexacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance
regulator gene
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles
indoles
benzodioxoles
quinolines
quinolines
---
https://www.has-sante.fr/jcms/p_3199558/fr/eliquis
2020
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
administration, oral
apixaban
apixaban
stroke
insurance, health, reimbursement
embolism
apixaban
Factor Xa Inhibitors
Factor Xa Inhibitors
adult
atrial fibrillation
hemorrhage
pyrazoles
pyridones
pyrazoles
pyridones
---
https://www.has-sante.fr/jcms/p_3193768/fr/vitrakvi
2020
false
false
false
France
larotrectinib
insurance, health, reimbursement
child
Infantile Fibrosarcoma
fibrosarcoma
sarcoma
neoplasm metastasis
treatment outcome
adult
administration, oral
protein kinase inhibitors
Product containing only larotrectinib in oral dose form (medicinal product form)
evaluation of the transparency committee
larotrectinib
pyrazoles
pyrimidines
---
https://www.has-sante.fr/jcms/p_3191487/fr/rapiscan
2020
false
false
false
France
regadenoson
fractional flow reserve, myocardial
diagnostic uses of chemicals
regadenoson
insurance, health, reimbursement
coronary stenosis
coronary angiography
evaluation of the transparency committee
purines
pyrazoles
---
https://pharmactuel.com/index.php/pharmactuel/article/view/1321
2020
Canada
journal article
chemotherapy
drug therapy
has patient
apixaban
Chemotherapy
patients
chemotherapy, nos
pyrazoles
pyridones
---
https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
darolutamide
darolutamide
darolutamide
prostatic neoplasms, Castration-Resistant
administration, oral
Product containing only darolutamide in oral dose form (medicinal product form)
androgen receptor antagonists
androgen receptor antagonists
product surveillance, postmarketing
adult
aged
drug interactions
survival analysis
drug evaluation, preclinical
pyrazoles
pyrazoles
---
https://www.has-sante.fr/jcms/p_3181104/fr/imbruvica
2020
false
false
false
France
adult
insurance, health, reimbursement
treatment outcome
drug therapy, combination
Rituximab
waldenstrom macroglobulinemia
ibrutinib
ibrutinib
administration, oral
protein kinase inhibitors
evaluation of the transparency committee
ibrutinib
pyrazoles
pyrimidines
---
https://www.oncorif.fr/wp-content/uploads/2019/05/Jakavi_patient.pdf
2019
false
false
false
false
France
French
guidelines for drug use
patients guideline
ruxolitinib
ruxolitinib
pyrazoles
tablets
tablets
---
https://ansm.sante.fr/informations-de-securite/Anticoagulants-Oraux-Directs-AODs-apixaban-Eliquis-R-rivaroxaban-Xarelto-R-dabigatran-Pradaxa-R-et-edoxaban-Lixiana-R-Roteas-R-non-recommandes-chez-les-patients-presentant-un-Syndrome-des-Antiphospholipides-SAPL
2019
false
false
false
France
French
pharmacovigilance note
guidelines for drug use
administration, oral
apixaban
Rivaroxaban
edoxaban
anticoagulants
Dabigatran
recurrence
risk
antiphospholipid syndrome
thrombosis
thrombosis
pyrazoles
pyridones
pyridines
thiazoles
---
https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
antineoplastic agents
antineoplastic agents
administration, oral
adult
neoplasms
neoplasms
product surveillance, postmarketing
child
gene fusion
receptor, trka
receptor, trkb
receptor, trkc
adolescent
aged
drug interactions
pregnancy
breast feeding
receptor, trka
receptor, trkb
receptor, trkc
protein kinase inhibitors
protein kinase inhibitors
drug evaluation, preclinical
larotrectinib
Tyrosine Kinase Inhibitors
larotrectinib
larotrectinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
---
https://www.has-sante.fr/portail/jcms/c_2826829/fr/eliquis
2018
false
false
false
false
France
French
evaluation of the transparency committee
apixaban
apixaban
pyrazoles
pyridones
---
https://www.has-sante.fr/portail/jcms/c_2851086/fr/les-anticoagulants-oraux
2018
false
false
false
France
French
guidelines for drug use
anticoagulants
anticoagulants
administration, oral
antivitamins K
antivitamins K
atrial fibrillation
drug overdose
apixaban
Dabigatran
antithrombins
Factor Xa Inhibitors
Rivaroxaban
edoxaban
Direct factor Xa inhibitors
direct thrombin inhibitors
pregnancy
patient compliance
continuity of patient care
hemorrhage
surgical procedures, operative
blood loss, surgical
hemorrhage
vitamin k antagonists
fluindione
acenocoumarol
warfarin
pyridines
thiazoles
phenindione
phenindione
indenes
4-hydroxycoumarins
vitamin K
vitamin K
indenes
4-hydroxycoumarins
vitamin K
pyrazoles
pyridones
---
http://www.has-sante.fr/portail/jcms/c_2746213/fr/imbruvica
http://www.has-sante.fr/portail/jcms/c_2746213/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk
2017
false
false
false
France
French
evaluation of the transparency committee
guidelines for drug use
ibrutinib
ibrutinib
administration, oral
treatment outcome
ibrutinib
adult
protein kinase inhibitors
protein kinase inhibitors
IBtk protein, human
IBtk protein, human
insurance, health, reimbursement
orphan drug production
leukemia, lymphocytic, chronic, B-Cell
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
carrier proteins
carrier proteins
---
http://kce.fgov.be/fr/publication/report/anticoagulation-et-fibrillation-auriculaire
2017
false
false
false
Belgium
French
anticoagulants
anticoagulants
atrial fibrillation
treatment outcome
stroke
continuity of patient care
Cost-Benefit analysis
medication adherence
risk assessment
hemorrhage
vitamin K
antivitamins K
Rivaroxaban
edoxaban
Dabigatran
apixaban
Factor Xa Inhibitors
antithrombins
belgium
technical report
drug information
comparative study
anticoagulants
economic evaluation
drug monitoring
new oral anticoagulant
indenes
4-hydroxycoumarins
pyridines
thiazoles
pyrazoles
pyridones
---
http://www.has-sante.fr/portail/jcms/c_2748397/fr/revolade
2017
false
false
false
France
French
evaluation of the transparency committee
eltrombopag
eltrombopag
administration, oral
Product containing precisely eltrombopag 75 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing eltrombopag (medicinal product)
tablets
Oral Suspension Dosage Form
hydrazines
pyrazoles
benzoates
---
https://www.has-sante.fr/portail/jcms/c_2770187/fr/imbruvica-lcm
https://www.has-sante.fr/portail/jcms/c_2770187/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk-lcm
2017
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
insurance, health, reimbursement
treatment outcome
ibrutinib
ibrutinib
orphan drug production
ibrutinib
adult
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
lymphoma, mantle-cell
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
survival analysis
comparative effectiveness research
temsirolimus
guidelines for drug use
Progression-Free survival
Tyrosine Kinase Inhibitors
ibrutinib
ibrutinib
carrier proteins
pyrazoles
pyrimidines
pyrazoles
pyrimidines
sirolimus
sirolimus
disease-free survival
---
https://www.anses.fr/fr/system/files/ERCA2017SA0183.pdf
2017
false
false
false
France
French
threshold limit values
scientific and technical information
france
administration, oral
fipronil
eggs
Pizza (substance)
Cookie and/or cracker (substance)
Sauce (substance)
Seasoning (substance)
Pasta (substance)
bread
Savory dishes (substance)
Dessert (substance)
Egg product (substance)
Egg noodles (substance)
Egg and egg product industries
Cake (substance)
Sandwich - dietary (substance)
Custard (substance)
fipronil
pyrazoles
pyrazoles
---
https://www.anses.fr/fr/system/files/AUT2017SA0178.pdf
2017
false
false
false
France
French
scientific and technical information
threshold limit values
fipronil
fipronil
eggs
france
Egg, Poultry
insecticides
belgium
risk factors
risk management
poultry
environmental exposure
pyrazoles
pyrazoles
---
https://www.anses.fr/fr/content/evaluation-des-risques-li%C3%A9s-%C3%A0-la-consommation-d%E2%80%99%C5%93ufs-et-de-produits-%C3%A0-base-d%E2%80%99%C5%93ufs-contamin%C3%A9s
2017
false
false
false
France
French
threshold limit values
fipronil
fipronil
eggs
eggs
france
Egg, Poultry
belgium
risk factors
poultry
netherlands
risk assessment
evaluation studies
eating
Egg product (substance)
pesticide residues
pesticide residues
Egg intake (observable entity)
pyrazoles
pyrazoles
---
http://www.cochrane.org/fr/CD007654/les-effets-long-terme-des-medicaments-amaigrissants-chez-les-personnes-presentant-une-elevation-de
2016
false
United Kingdom
France
French
meta-analysis
treatment outcome
hypertension
anti-obesity agents
overweight
appetite depressants
lactones
sibutramine
piperidines
pyrazoles
cyclobutanes
french abstract
Rimonabant
Orlistat
---
REVOLADE (eltrombopag) - Risk of Severe Hepatotoxicity
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59916a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
Chemical and Drug Induced Liver Injury
eltrombopag
eltrombopag
guidelines for drug use
continuity of patient care
drug monitoring
administration, oral
alanine transaminase
aspartate aminotransferases
bilirubin
blood chemical analysis
product surveillance, postmarketing
canada
patient education handout
hydrazines
pyrazoles
benzoates
---
http://www.has-sante.fr/portail/jcms/c_2671734/fr/revolade-ams
http://www.has-sante.fr/portail/jcms/c_2671734/fr/revolade-eltrombopag-agoniste-des-recepteurs-a-la-thrombopoietine-ams
2016
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
guidelines for drug use
eltrombopag
eltrombopag
administration, oral
eltrombopag
anemia, aplastic
adult
receptors, thrombopoietin
hydrazines
pyrazoles
benzoates
hydrazines
pyrazoles
benzoates
---
http://www.health.belgium.be/fr/avis-9241-neonicotinoides
2016
false
false
false
Belgium
French
guideline
effective
health impact assessment
fipronil
biodiversity
health
evaluation studies as topic
health
pyrazoles
---
http://www.has-sante.fr/portail/jcms/c_2742289/fr/imbruvica
http://www.has-sante.fr/portail/jcms/c_2742289/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk
2016
false
false
false
false
France
French
evaluation of the transparency committee
administration, oral
insurance, health, reimbursement
treatment outcome
ibrutinib
ibrutinib
ibrutinib
adult
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
waldenstrom macroglobulinemia
guidelines for drug use
Tyrosine Kinase Inhibitors
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
carrier proteins
---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles
---
ADEMPAS (riociguat) - New Contraindication for Patients with Pulmonary Hypertension
Associated with Idiopathic Interstitial Pneumonias (PH-IIP)
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/59816a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
hypertension, pulmonary
riociguat
riociguat
administration, oral
idiopathic interstitial pneumonias
Contraindications, Procedure
pyrazoles
pyrimidines
Contraindications, Drug
---
https://www.revmed.ch/RMS/2016/RMS-N-529/Anticoagulants-oraux-directs-quelques-considerations-pratiques
2016
false
false
false
Switzerland
French
journal article
administration, oral
anticoagulants
thromboembolism
thromboembolism
Direct factor Xa inhibitors
direct thrombin inhibitors
aged
neoplasms
liver cirrhosis
obesity
continuity of patient care
drug interactions
antidotes
stroke
treatment outcome
anticoagulants
Dabigatran
Rivaroxaban
apixaban
edoxaban
anticoagulants
Contraindications, Procedure
pyrazoles
pyridones
pyridines
thiazoles
Contraindications, Drug
---
https://www.revmed.ch/RMS/2016/RMS-N-542/Anticoagulants-oraux-directs-ACOD-une-aide-a-la-prescription-dans-la-pratique-quotidienne
2016
false
false
false
Switzerland
French
journal article
venous thromboembolism
antithrombins
administration, oral
atrial fibrillation
Evidence-Based medicine
guidelines for drug use
recurrence
venous thromboembolism
antithrombins
Direct factor Xa inhibitors
Factor Xa Inhibitors
Factor IIa
dabigatran etexilate
Dabigatran
Rivaroxaban
apixaban
edoxaban
drug interactions
continuity of patient care
clinical chemistry tests
kidney function tests
hemorrhage
surgical procedures, operative
heparin
antivitamins K
patient safety
factor IIa
prothrombin
pyrazoles
pyridones
pyridines
thiazoles
indenes
4-hydroxycoumarins
vitamin K
vitamin K
---
http://www.centreantipoisons.be/professionnels-de-la-sant/articles-pour-professionnels-de-la-sant/nouveaux-anticoagulants-par-voie
2016
false
false
false
Belgium
French
Dutch
practice guideline
administration, oral
Rivaroxaban
rivaroxaban
anticoagulants
apixaban
Factor Xa Inhibitors
hemorrhage
hemorrhage
hemorrhage
apixaban
dabigatran etexilate
Dabigatran
antithrombins
hospitalization
ambulatory care
pyrazoles
pyridones
---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
---
https://minerva-ebp.be/fr/analyses-en-ligne/300
2015
false
true
false
minerva-ebm.be
Belgium
French
french abstract
scientific and technical information
hemorrhage
antivitamins K
apixaban
indenes
4-hydroxycoumarins
vitamin K
pyrazoles
pyridones
---
http://www.has-sante.fr/portail/jcms/c_2049868/fr/imbruvica
http://www.has-sante.fr/portail/jcms/c_2049868/fr/imbruvica-ibrutinib-inhibiteur-de-tyrosine-kinase-de-bruton-btk
2015
false
false
false
France
French
evaluation of the transparency committee
administration, oral
insurance, health, reimbursement
treatment outcome
ibrutinib
ibrutinib
orphan drug production
ibrutinib
adult
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
lymphoma, mantle-cell
leukemia, lymphocytic, chronic, B-Cell
leukemia, lymphocytic, chronic, B-Cell
IBtk protein, human
protein-tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
survival analysis
guidelines for drug use
Tyrosine Kinase Inhibitors
ibrutinib
ibrutinib
carrier proteins
pyrazoles
pyrimidines
pyrazoles
pyrimidines
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63012197
2015
false
false
false
France
French
summary of product characteristics
package leaflet
ibrutinib
capsules
ibrutinib
ibrutinib
pyrazoles
pyrimidines
---
http://www.sciencedirect.com/science/article/pii/S0755498214002590
2014
false
false
false
France
French
atrial fibrillation
anticoagulants
administration, oral
anticoagulants
drug interactions
journal article
dabigatran etexilate
rivaroxaban
apixaban
apixaban
edoxaban
warfarin
factor xa
antithrombins
treatment outcome
renal insufficiency
age factors
Direct current cardioversion (procedure)
myocardial infarction
surgical procedures, operative
Factor Xa Inhibitors
anticoagulotherapy
Dabigatran
Rivaroxaban
pyridines
pyrazoles
pyridones
thiazoles
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61875550
2014
false
false
false
France
French
summary of product characteristics
pill, nos
dandruff
tablets
riociguat
compression, nos
seborrhea sicca
riociguat
riociguat
dandruff
pyrazoles
pyrimidines
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60203795
2014
false
false
false
France
French
summary of product characteristics
dandruff
riociguat
compression, nos
seborrhea sicca
riociguat
riociguat
tablets
pill, nos
dandruff
pyrazoles
pyrimidines
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60025054
2014
false
false
false
France
French
summary of product characteristics
seborrhea sicca
riociguat
riociguat
pill, nos
dandruff
riociguat
compression, nos
tablets
dandruff
pyrazoles
pyrimidines
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=66086562
2014
false
false
false
France
French
summary of product characteristics
tablets
riociguat
seborrhea sicca
riociguat
compression, nos
riociguat
dandruff
pill, nos
dandruff
pyrazoles
pyrimidines
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64832942
2014
false
false
false
France
French
summary of product characteristics
seborrhea sicca
riociguat
riociguat
pill, nos
dandruff
tablets
riociguat
compression, nos
dandruff
pyrazoles
pyrimidines
---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61902218
2014
false
false
false
France
French
summary of product characteristics
package leaflet
pill, nos
dandruff
apixaban
compression, nos
tablets
seborrhea sicca
apixaban
dandruff
pyrazoles
pyridones
---
http://www.has-sante.fr/portail/jcms/c_1761611/fr/adempas
2014
false
false
false
France
French
evaluation of the transparency committee
administration, oral
riociguat
hypertension, pulmonary
adult
drug therapy, combination
treatment outcome
Chronic thromboembolic pulmonary hypertension
orphan drug production
riociguat
guidelines for drug use
riociguat
pyrazoles
pyrimidines
pyrazoles
pyrimidines
---
http://www.cfp.ca/content/60/11/e504.full
2014
false
false
false
Canada
French
anticoagulants
journal article
antithrombins
apixaban
stroke
atrial fibrillation
venous thromboembolism
comparative study
treatment outcome
case reports
warfarin
anticoagulants
anticoagulotherapy
Rivaroxaban
Dabigatran
pyrazoles
pyridones
---
http://www.cfp.ca/content/60/11/e512.full
2014
false
false
false
Canada
French
journal article
anticoagulants
case reports
drug interactions
stroke
atrial fibrillation
venous thromboembolism
apixaban
food-drug interactions
preoperative care
anticoagulotherapy
Dabigatran
Rivaroxaban
pyrazoles
pyridones
---
https://www.ema.europa.eu/medicines/human/EPAR/Imbruvica
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
ibrutinib
ibrutinib
drug approval
europe
antineoplastic agents
antineoplastic agents
orphan drug production
leukemia, lymphocytic, chronic, B-Cell
lymphoma, mantle-cell
ibrutinib
leukemia, lymphocytic, chronic, B-Cell
administration, oral
capsules
IBtk protein, human
protein kinase inhibitors
protein kinase inhibitors
drug monitoring
continuity of patient care
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
ibrutinib
ibrutinib
pyrazoles
pyrimidines
pyrazoles
pyrimidines
carrier proteins
---
https://www.revmed.ch/RMS/2014/RMS-N-416/Pourquoi-quand-et-comment-doser-les-nouveaux-anticoagulants-oraux
2014
false
false
false
Switzerland
French
journal article
thromboembolism
continuity of patient care
drug monitoring
anticoagulants
administration, oral
rivaroxaban
apixaban
dabigatran etexilate
apixaban
risk factors
blood coagulation tests
kidney failure, chronic
factor xa
antithrombins
Factor Xa Inhibitors
Rivaroxaban
Dabigatran
pyrazoles
pyridones
---
https://www.revmed.ch/RMS/2014/RMS-N-416/Nouveaux-anticoagulants-oraux-donnees-pharmacologiques-a-connaitre-pour-la-pratique-clinique
2014
false
false
false
Switzerland
French
journal article
anticoagulants
administration, oral
antithrombins
factor xa
apixaban
thromboembolism
thromboembolism
drug interactions
renal insufficiency
hepatic insufficiency
aged
obesity
anticoagulants
antithrombins
Factor Xa Inhibitors
anticoagulotherapy
Rivaroxaban
Dabigatran
pyrazoles
pyridones
---
https://www.jle.com/fr/revues/medecine/met/e-docs/00/04/99/39/resume.phtml
2014
false
France
French
atrial fibrillation
anticoagulants
journal article
thrombosis
vitamin K
drug interactions
practice guideline
aged
risk assessment
apixaban
edoxaban
pyridines
thiazoles
pyrazoles
pyridones
antithrombins
anticoagulotherapy
Rivaroxaban
Dabigatran
antivitamins K
indenes
4-hydroxycoumarins
---
https://minerva-ebp.be/fr/article/65
2013
false
false
minerva-ebm.be
Belgium
French
venous thromboembolism
treatment outcome
critical appraisal or critical reading
pyrazoles
pyridones
fibrinolytic agents
apixaban
---
https://www.anses.fr/fr/system/files/DPR2011sa0207.pdf
2011
France
French
scientific and technical information
chelating agents
edetic acid
lignosulfuric acid
lignin
3-methylpyrazole
dicyandiamido
guanidines
pyrazoles
1,2,4-triazole
triazoles
edetic acid
N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid
---
https://minerva-ebp.be/fr/article/236
2011
false
true
false
false
minerva-ebm.be
Belgium
atrial fibrillation
stroke
pyrazoles
pyridones
critical appraisal or critical reading
thromboembolism
apixaban
aspirin
---
https://www.ema.europa.eu/medicines/human/EPAR/Zimulti
2008
United Kingdom
English
French
syndication feed
drug evaluation
obesity
piperidines
pyrazoles
treatment outcome
piperidines
pyrazoles
anti-obesity agents
adult
pregnancy
breast feeding
tablets
administration, oral
drug evaluation, preclinical
risk factors
drug interactions
piperidines
pyrazoles
piperidines
piperidines
pyrazoles
pyrazoles
piperidines
pyrazoles
piperidines
pyrazoles
receptor, cannabinoid, CB1
rimonabant
piperidines
pyrazoles
drug evaluation
package leaflet
summary of product characteristics
Rimonabant
---
https://rmlg.uliege.be/article/1699
2008
Belgium
French
piperidines
pyrazoles
receptor, cannabinoid, CB1
journal article
Rimonabant
---
https://www.ema.europa.eu/medicines/human/EPAR/Acomplia
2008
United Kingdom
French
English
syndication feed
Contraindications, Procedure
obesity
piperidines
piperidines
pyrazoles
pyrazoles
receptor, cannabinoid, CB1
drug evaluation
treatment outcome
adult
tablets
administration, oral
piperidines
pyrazoles
anti-obesity agents
piperidines
pyrazoles
piperidines
piperidines
pyrazoles
pyrazoles
risk factors
drug interactions
pregnancy
breast feeding
pyrazoles
piperidines
pyrazoles
piperidines
drug evaluation, preclinical
rimonabant
piperidines
pyrazoles
drug evaluation
package leaflet
summary of product characteristics
Contraindications, Drug
Rimonabant
---
http://www.lecrat.eu/?s=Rimonabant+-+Acomplia%C2%AE
2007
France
French
pregnancy
breast feeding
receptors, cannabinoid
piperidines
pyrazoles
anti-obesity agents
rimonabant
piperidines
pyrazoles
drug information
Rimonabant
---
https://minerva-ebp.be/fr/article/583
2007
false
minerva-ebm.be
Belgium
French
omeprazole
anti-inflammatory agents, non-steroidal
pyrazoles
sulfonamides
anti-ulcer agents
peptic ulcer hemorrhage
proton pump inhibitors
peptic ulcer hemorrhage
cyclooxygenase inhibitors
critical appraisal or critical reading
---
https://kce.fgov.be/fr/traitement-pharmacologique-et-chirurgical-de-lobesite-prise-en-charge-residentielle-des-enfants
2006
false
Belgium
French
English
pediatric obesity
obesity
obesity
child
belgium
adolescent
Cost-Benefit analysis
liability, legal
bariatric surgery
treatment outcome
anti-obesity agents
lactones
appetite depressants
cyclobutanes
piperidines
pyrazoles
weight loss
bariatric surgery
adult
patient care management
health policy guidelines
health technology assessment
---
https://minerva-ebp.be/fr/article/637
2006
false
false
minerva-ebm.be
Belgium
French
weight loss
obesity
treatment outcome
piperidines
pyrazoles
cardiovascular diseases
risk factors
receptor, cannabinoid, CB1
adult
piperidines
pyrazoles
critical appraisal or critical reading
Rimonabant
---
https://medias.vie-publique.fr/data_storage_s3/rapport/pdf/054000278.pdf
2005
France
French
pyrazoles
insecticides
environmental exposure
legislation, drug
occupational exposure
pyrazoles
pyrazoles
insecticides
risk assessment
technical report
evaluation studies
---
https://www.amub-ulb.be/system/files/rmb/old/192
2005
false
Belgium
French
Ezetimibe
hypolipidemic agents
fatty acids, Omega-3
piperidines
niacin
anticholesteremic agents
pyrazoles
docosahexaenoic acids
eicosapentaenoic acid
Omacor
drug combinations
journal article
Rimonabant
---